McKesson
Pharmaceuticals and medical supplies distributor.
Agile Delivery Manager
+ Annual bonus + Long-term incentive opportunities
About the job
- 10+ years leading large-scale technology delivery in enterprise environments.
- Prior people leadership experience managing Scrum Masters, Delivery Leads, or Technical Program Managers.
- Proven ownership of delivery outcomes across multiple teams, programs, or value streams.
- Strong coaching, talent development, and performance management capabilities.
- Demonstrated ability to influence Directors, VPs, and senior leaders through data and insight.
- Deep understanding of agile frameworks, including Scrum, SAFe, and Kanban, and enterprise delivery models.
- Experience operating in regulated or compliance-driven environments.
- Strong command of delivery metrics, governance, and risk management practices.
- Proficiency with Jira, Confluence, and related delivery tools.
- Excellent communication, organizational, and cross-functional collaboration skills.
- Currently authorized to work in the United States on a full-time basis without employer support or sponsorship now or in the future.
- Own delivery outcomes across teams or value streams through Scrum Masters, ensuring predictable, high-quality execution aligned to business priorities and enterprise standards.
- Establish and enforce delivery models, cadences, and governance aligned to Ontada’s Agile Delivery Lifecycle.
- Partner with Product and Engineering leadership to ensure work is properly sequenced, funded, and staffed for predictable execution.
- Provide oversight of release planning, milestone management, cross-team dependencies, and delivery commitments.
- Proactively identify and mitigate systemic delivery risks, escalating with options and recommendations when tradeoffs are required.
- Serve as the senior agile authority supporting delivery transformation across assigned teams.
- Oversee iteration-based planning and execution, including capacity allocation, flow efficiency, risk identification, mitigation, tracking, and reporting.
- Oversee PlainView-related activities and reports.
- Deliver Scrum Master responsibilities for one team.
- Directly manage Scrum Masters, including goal setting, coaching, feedback, and performance management.
- Set clear expectations for role maturity, scope ownership, and delivery excellence.
- Mentor Scrum Masters and assess readiness for expanded scope or promotion.
- Build a culture of accountability, collaboration, and continuous improvement across the delivery organization.
- Act as a trusted delivery partner to Product, Engineering, QA, and business leaders.
- Provide executive-level visibility into delivery health, risks, dependencies, and outlook.
- Facilitate governance forums, escalation paths, and decision checkpoints.
- Translate complex delivery challenges into clear insights, options, and recommendations for senior leadership.
- Ensure adherence to enterprise governance, regulatory controls, and audit requirements across delivery efforts.
- Oversee scope management, change control, and delivery discipline for milestone-driven initiatives.
- Ensure delivery artifacts, metrics, and evidence are consistently produced and audit-ready.
- Maintain alignment with ServiceNow change management and other enterprise processes.
- Define, monitor, and act on delivery KPIs, metrics, and dashboards.
- Understand and implement industry best practices.
- Publish and maintain release-level information radiators.
- Analyze trends based on agile maturity surveys to identify systemic issues impacting predictability, quality, or throughput.
- Lead continuous improvement initiatives across delivery practices, tooling, and ways of working.
- Support Product and Scrum Teams in prioritization, sizing, and business value definition.
- Conduct Valuable Scrum of Scrums and drive action items to closure.
- Contribute to the evolution of Ontada’s Agile Delivery Lifecycle and enterprise agile maturity.
About the company
McKesson is a global healthcare distributor and services provider. It buys pharmaceuticals and medical products from manufacturers and distributes them to pharmacies, hospitals, and other healthcare facilities, acting as an intermediary in the supply chain. Its core work includes logistics and supply chain management, ensuring medicines and medical supplies reach customers on time and safely. McKesson also offers technology solutions to help healthcare providers manage operations and procurement. Compared with competitors, it leverages a very large-scale network and integrated services—combining distribution, logistics, and technology—across providers, pharmacies, and manufacturers. The company aims to support the healthcare system by keeping essential medical supplies available and helping healthcare facilities run more efficiently, ultimately improving patient care.
Company Size
10,001+
Company Stage
IPO
Headquarters
Irving, Texas
Founded
1833
Get referred to McKesson
See people who can refer or advise you
Simplify's Take
What believers are saying
- McKesson signed to buy Precision Medicine Group for $2.25 billion on August 25, 2026.
- Precision adds CRO, biomarker intelligence, lab services, and commercialization support to oncology.
- McKesson raised its outlook and returned $2.5 billion through buybacks this year.
What critics are saying
- ShinyHunters breached third-party apps on August 25, 2026, and demanded $55.2 million.
- HIBP tied the leak to 6.4 million breached accounts on September 10, 2026.
- Another identity breach would destroy trust with hospitals and pharmacies reliant on McKesson.
What makes McKesson unique
- McKesson moves roughly one-third of North American prescriptions through its distribution network.
- Oncology & Multispecialty revenue reached $14.2 billion in Q1 fiscal 2026.
- Sarah Cannon, Ontada, and U.S. Oncology Network create a rare care-services moat.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Performance Bonus
401(k) Company Match
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%Modivcare names new CEO of personal care services; LifeCare appoints new COO. Modivcare names new CEO of personal care services, chief corporate affairs officer. Modivcare named Marshalina "Marsha" Ramos CEO of the personal care services (PCS) business on Sept. 8, where she will oversee the company's PCS portfolio. Prior to joining Modivcare, Ramos served as founder and CEO of home care and hospice advisory firm Visionary Group. She also acted as president and chief operating officer of home-based care provider Premier Home Health Care and held numerous senior roles at home care provider VNS Health. "[Ramos] has built and stabilized multi-state home care operations, navigated complex regulatory and managed care environments and earned the loyalty of the teams she has led," Modivcare Board of Managers Chair Leslie Norwalk said in a statement. "With Marsha's addition to the Modivcare team, each of our businesses is now led by a seasoned executive with deep industry expertise and a strong understanding of the markets they serve." The company tapped Matt Williams to serve as chief corporate affairs officer effective Sept. 1. He will oversee Modivcare's corporate reputation and communications, regulatory affairs and public policy and focus on bolstering the company's stakeholder engagement and advocacy. Williams previously served as vice president of government affairs at McKesson, a medical supplies and pharmaceutical healthcare company, and major pharmaceutical manufacturer AbbVie. "I'm honored to join Modivcare at an important time for the company," Williams said in a statement. "I look forward to working alongside teams across the organization to strengthen our reputation, deepen relationships with policymakers, clients and other stakeholders, and advance our mission." Denver-based Modivcare provides nonemergency medical transportation, personal care, remote monitoring and integrative supportive care across 35 states. LifeCare Home Health & Hospice Family appoints new chief operating officer. Dr. Nasser Khan joined LifeCare Home Health & Hospice Family as president and COO, where he will manage operations across the company's portfolio and scale growth and integrations. Khan previously served as COO of behavioral health company Acadia Healthcare, in addition to roles at specialty pharmacy solutions provider Shields Health Solutions, kidney dialysis provider DaVita Kidney Care, preventive diagnostics clinic Biograph and global management consulting company McKinsey & Company. "Dr. Khan brings a rare combination of clinical insight, operational experience and demonstrated leadership at scale," LifeCare Home Health & Hospice Family CEO Dean Alverson said in a statement. "As LifeCare continues to grow, his experience developing teams, strengthening operations and bringing organizations together will be invaluable." Irving, Texas-based LifeCare Home Health & Hospice Family offers home health, hospice and in-home care throughout 39 locations in Texas, Florida, Georgia, Nevada and Arizona. BrightSpring taps Alliance VP as vice president of federal government relations. Hillary Loeffler joined BrightSpring Health Services (Nasdaq: BTSG) as vice president of federal government relations in August 2026, according to her LinkedIn profile. Before joining BrightSpring, Loeffler served as vice president of policy and regulatory affairs for the National Alliance for Care at Home and held various roles at the Centers for Medicare & Medicaid Services (CMS) for over 13 years. Louisville, Kentucky-based BrightSpring Health Services provides home health, personal care, infusions and specialty pharmaceuticals, hospice and other services throughout all 50 states. Senior1Care names cate Palace president of Northeast region. Cate Palace will serve as the president of the Northeast region for Senior1Care, where she is charged with handling growth and operations in three Indiana cities. Palace has over 20 years of experience including leading home care, skilled nursing, assisted rehabilitation and other agencies providing services for older adults. "Palace understands senior care from both a clinical and operational perspective and recognizes the role relationships play in earning the trust of families, healthcare partners and the communities we serve," Senior1Care CEO Kyle Bossung said in a statement. "I'm grateful she chose to bring that perspective to Senior1Care and look forward to having her as part of our leadership team." Senior1Care, based in Mishawaka, Indiana, provides personal care and companionship services across the Angola, Elkhart, Fort Wayne, Indianapolis, South Bend and Warsaw regions of Indiana. Porter appoints Jeff Fox as chief growth officer. Porter named Jeff Fox chief growth officer. He is charged with leading the company's growth strategy, relationships with health plans, strategic partnerships and technology expansion. Baltimore-based Porter is a healthcare IT and services platform that offers care coordination and in-home care assessments for families, individuals, payers and at-risk providers. Fox previously led Atrio Health Plans as CEO, where he aided the firm's expansion into new markets, and oversaw Gorman Health Group for 17 years as president and CEO. "Jeff knows this business and the people it serves," Porter Founder, CEO and Chairman John Criswell said in a statement. "He understands how health plans work, the pressures they face, and what is at stake for the people who depend on them. That experience will help Porter grow with purpose and deliver at a greater scale." Companies featured in this article: MK Manoylov is a Senior Reporter at Home Health Care News. Their work has appeared in publications including WebMD, Business Insider and LiveScience, in addition to governmental reports from the U.S. Department of the Treasury. MK earned a master's degree in journalism in the Science, Health and Environmental Reporting (SHERP) from New York University.
Promising medical stocks to research - september 10th. Boston Scientific, Tenon Medical, and McKesson are the three Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of publicly traded companies involved in healthcare, such as pharmaceutical and biotechnology firms, medical-device manufacturers, hospitals, and health-insurance providers. Investors may buy them for potential growth, income, or defensive characteristics, but their performance can be affected by regulation, clinical-trial results, patent changes, and healthcare demand. These companies had the highest dollar trading volume of any Medical stocks within the last several days. Track Stocks Bonds Boston Scientific (BSX). Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. Discover more Access Premium News Track Market Trends Tenon Medical (TNON). Tenon Medical, Inc., a medical device company, engages in the development of surgical implant systems to treat severe lower back pain in the United States and Puerto Rico. The company offers CATAMARAN SI-Joint Fusion System to fuse sacroiliac joints (SI-Joints) to treat SI-Joint dysfunction that often causes severe lower back pain; and features fixation device that passes through the axial and sagittal planes of the ilium and sacrum, as well as transfixes the SI joints. McKesson (MCK). McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.
McKesson - 6,404,340 breached accounts. 2026-09-10 09:09 In August 2026, healthcare and pharmaceutical company McKesson was targeted in a ShinyHunters "pay or leak" extortion campaign. The group subsequently published a substantial corpus of data they alleged was sourced from the company, which included 6.4M unique email addresses among other personal and corporate data attributes. The impacted data related to a range of individuals and roles, including marketing campaign recipients, patients, staff and healthcare provider contacts. In McKesson's disclosure notice, the company advised it had identified unauthorised access to "certain third-party applications and the exfiltration of certain data was associated with a subset of customers within its Oncology & Multispecialty and Medical-Surgical business units", but had "reasonable assurance of no ongoing unauthorized activity". Read the original article: In May 2026, the dental benefits administrator DentaQuest was the target of a ShinyHunters "pay or leak" extortion campaign that resulted in the group publicly publishing hundreds of gigabytes of data allegedly obtained from the company. The data included 2.6M unique email addresses along with names, addresses and phone numbers... Hacking & Cracking June 4, 2026 Healthcare company McKesson acknowledged a data breach. ShinyHunters claims to have stolen hundred of millions of records August 31, 2026 Healthcare company McKesson disclosed a cybersecurity incident in which hackers got into third-party applications and stole data. McKesson is a major U.S... August 31, 2026
McKesson acquires Precision Medicine from Blackstone. Posted on September 9, 2026 TEXAS and MARYLAND, UNITED STATES - McKesson Corporation signed a definitive agreement to acquire Precision Medicine Group from Blackstone for approximately $2.25 billion. The purchase adds biomarker intelligence, laboratory services, a global contract research organization, market access consulting, and drug commercialization support to McKesson's oncology and specialty care portfolio. Closing is subject to customary regulatory clearances. Oncology capital strategy anchors $2.25 billion deal. According to a report from Lawrence Evans, McKesson said the acquisition of Precision Medicine Group aligns with its strategy of concentrating capital in oncology and specialty care. The company's Oncology and Multispecialty segment posted $14.2 billion in revenue in fiscal first-quarter 2026, a 33% year-over-year increase, and McKesson has committed to this segment as its primary growth axis. The deal gives McKesson an owned global contract research organization (CRO), a biomarker intelligence platform, and laboratory analysis capabilities: knowledge process outsourcing (KPO) functions the company had previously accessed through external partnerships rather than owned assets. Blackstone exit marks precision oncology payoff. Precision Medicine Group said its market access consulting and drug commercialization support services are built to serve pharmaceutical manufacturers across the full clinical-to-commercial lifecycle, extending McKesson's role beyond drug distribution into research and launch strategy. Blackstone's exit at approximately $2.25 billion reflects the premium that large health services acquirers now place on scaled managed services platforms in oncology, where CRO capabilities and biomarker data assets command valuations above those of traditional distribution businesses. McKesson said it does not anticipate any disruption to Precision Medicine Group's existing client relationships through or following the close of the transaction. The McKesson-Precision Medicine Group acquisition reflects accelerating consolidation in oncology services, where distributors and health systems are acquiring clinical research and market access capabilities once confined to standalone CRO firms. For the healthcare outsourcing sector, the transaction signals that pharmaceutical manufacturers increasingly expect outsourced partners to manage the full pathway from laboratory biomarker analysis through drug launch rather than discrete functions delivered by separate vendors. At $2.25 billion, the deal illustrates that precision medicine services platforms carrying robust data assets and commercialization expertise command significant strategic multiples. As oncology drug pipelines grow in complexity, the ability to combine CRO operations with go-to-market strategy is becoming a structural differentiator for companies operating at the intersection of health services and outsourced pharmaceutical support. FREE BPO MATCH Evaluating outsourcing partners after a deal? BPO specialists for due diligence and integration - free match 5,200+ matches made Disclosure: Outsource Accelerator uses AI tools in the backend of its editorial workflow. Every article is reviewed and verified by a human editor before publication. Stay ahead of the outsourcing industry. Join thousands of business leaders who rely on Outsource Accelerator for the news, trends, and expert insights that matter. Subscribe to our free newsletter and never miss an update.
Supply chain vulnerability isn't just about code. Jason Nickerson has spent years talking about the risks of centralized infrastructure in the hosting world, but the same consolidation that makes cloud computing efficient is creating massive single points of failure in its healthcare system. McKesson, a titan that effectively keeps the lights on for hospitals and pharmacies across the United States, is currently dealing with a massive breach and subsequent service degradation. According to a recent report, hackers are claiming to have walked away with millions of patient records while the company struggles to maintain its normal distribution of medicines and devices. This isn't just a matter of leaked names and dates; it is an operational bottleneck that stops the flow of physical goods to people who actually need them. The cost of consolidation. In the hosting business, if a major control panel or infrastructure provider has an outage, Jason Nickerson see it as a business catastrophe. When it happens to a medical distributor, it becomes a public health crisis. The business implication here is clear: its push toward hyper-efficiency through massive, centralized distributors has created a landscape where one successful breach can paralyze an entire sector. For McKesson, the challenge isn't just the PR nightmare of stolen data - it's the reality that their systems are so intertwined with their logistics that the breach has physically slowed down their ability to deliver products. Jason Nickerson is seeing a trend where attackers no longer just want to encrypt your files for a quick payday. They are targeting the friction points of the economy. If you can disrupt the distribution of medicine, you aren't just holding data hostage; you're holding the supply chain hostage. This puts a level of pressure on a company that a standard database leak simply can't match. It's a calculated move to force a settlement by making the operational pain unbearable. I've seen enough server migrations to know that recovery is never as fast as the initial press release suggests. If they are already admitting to service degradation, the IT teams in those distribution centers are likely having a very long month. The long view. Security is no longer a department you fund just to check a box for your insurance provider. In a world where your digital integrity dictates your physical output, failing to secure the perimeter is the same as locking the front door but leaving the loading dock wide open. Jason Nickerson need to stop treating data breaches as isolated IT incidents and start viewing them as the fundamental business risks they have become.